false
English
Catalog
2023 World Conference on Lung Cancer (Posters)
EP12.01. Adding Amivantamab as a Salvage Strategy ...
EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC - PDF(Slides)
Back to course
Pdf Summary
A study was conducted to evaluate the efficacy and safety of adding amivantamab as a salvage therapy for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who had disease progression after treatment with EGFR TKIs (osimertinib or mobocertinib). The study included 13 patients, with 8 in Group A (osimertinib) and 5 in Group B (mobocertinib), who received amivantamab on top of their previous EGFR TKI. The objective response rate (ORR) was 37.5% in Group A and 60% in Group B. The median duration of therapy was 2.3 months in Group A and 5.5 months in Group B. The median progression-free survival was 4.7 months in both groups. The safety profile of amivantamab was mainly driven by grade 3 toxicity, such as nausea, diarrhea, and skin rash. A total of 16% of patients experienced a grade 3 infusion reaction. Overall, adding amivantamab to previous EGFR TKI treatment was found to be feasible and showed clinically significant response rates. The study suggests further research to profile the subgroup of patients and conduct valid prospective analysis.
Asset Subtitle
Nir Peled
Meta Tag
Speaker
Nir Peled
Topic
Metastatic NSCLC: Targeted Therapy - EGFR/HER2
Keywords
amivantamab
salvage therapy
EGFR-mutated non-small cell lung cancer
disease progression
EGFR TKIs
osimertinib
mobocertinib
objective response rate
progression-free survival
grade 3 toxicity
×
Please select your language
1
English
5
普通话
11
Dutch